WS
RGLS

Wedbush Securities’s Regulus Therapeutics RGLS Stock Holding History

Wedbush Securities’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7,020
Closed -$36K – 961
2020
Q3 		$36K Buy
7,020
+4,962
+241% +$32.7K ﹤0.01% 901
2020
Q2 		$14K Sell
2,058
-16
-0.8% -$105 ﹤0.01% 948
2020
Q1 		$10K Sell
2,074
-12
-0.6% -$105 ﹤0.01% 873
2019
Q4 		$19K Sell
2,086
-2,031
-49% -$14.1K ﹤0.01% 984
2019
Q3 		$30K Buy
4,117
+779
+23% +$6.34K ﹤0.01% 963
2019
Q2 		$42K Sell
3,338
-1,011
-23% -$11.6K ﹤0.01% 956
2019
Q1 		$44K Buy
4,349
+1,075
+33% +$11.7K ﹤0.01% 898
2018
Q4 		$30K Buy
3,274
+1,973
+152% +$32.7K ﹤0.01% 807
2018
Q3 		$31K Buy
1,301
+614
+89% +$20.2K ﹤0.01% 880
2018
Q2 		$54K Sell
687
-584
-46% -$48.3K 0.01% 837
2018
Q1 		$109K Sell
1,271
-173
-12% -$23.1K 0.01% 750
2017
Q4 		$180K Sell
1,444
-50
-3% -$6.33K 0.02% 733
2017
Q3 		$224K Sell
1,494
-169
-10% -$21.3K 0.03% 661
2017
Q2 		$197K Buy
1,663
+155
+10% +$25.9K 0.03% 709
2017
Q1 		$299K Buy
1,508
+779
+107% +$148K 0.04% 538
2016
Q4 		$197K Buy
729
+459
+170% +$149K 0.03% 669
2016
Q3 		$107K Sell
270
-122
-31% -$50.2K 0.02% 746
2016
Q2 		$136K Buy
392
+119
+44% +$85.2K 0.02% 677
2016
Q1 		$227K Sell
273
-20
-7% -$15.9K 0.04% 540
2015
Q4 		$307K Sell
293
-426
-59% -$427K 0.06% 393
2015
Q3 		$564K Sell
719
-57
-7% -$58.5K 0.11% 199
2015
Q2 		$1.02M Buy
776
+391
+102% +$631K 0.19% 122
2015
Q1 		$783K Buy
+385
New +$837K 0.13% 171

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wedbush Securities's RGLS Position: Q4 2020 in Review

Wedbush Securities sold out of Regulus Therapeutics (RGLS) in Q4 2020, closing a stake of 7,020 shares — an estimated $36K sold.

Wedbush Securities first reported a position in RGLS in Q1 2015 and held it in 23 quarters. The position peaked at $1.02M in Q2 2015. 31 funds tracked by Wall St. Rank hold RGLS as of Q4 2020.

  • Wedbush Securities reported no remaining Regulus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 7,020 Regulus Therapeutics shares in Q4 2020, an estimated $36K.
  • Wedbush Securities first reported a position in Regulus Therapeutics in Q1 2015 and held it in 23 quarters.
  • Wedbush Securities's Regulus Therapeutics position peaked at $1.02M in Q2 2015.
  • 31 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.